Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Denali Therapeutics (DNLI) Net Margin (2018 - 2023)

Denali Therapeutics (DNLI) has disclosed Net Margin for 6 consecutive years, with 41.53% as the latest value for Q4 2023.

  • On a quarterly basis, Net Margin rose 42899325.0% to 41.53% in Q4 2023 year-over-year; TTM through Sep 2024 was 138.01%, a 16232.0% increase, with the full-year FY2023 number at 43.94%, up 954968.0% from a year prior.
  • Net Margin was 41.53% for Q4 2023 at Denali Therapeutics, up from 7841.59% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 3667.66% in Q2 2023 to a low of 429034.78% in Q4 2022.
  • A 5-year average of 37750.52% and a median of 613.76% in 2020 define the central range for Net Margin.
  • Peak YoY movement for Net Margin: crashed -42843337bps in 2022, then skyrocketed 42899325bps in 2023.
  • Denali Therapeutics' Net Margin stood at 204.73% in 2019, then crashed by -541bps to 1313.03% in 2020, then skyrocketed by 54bps to 601.41% in 2021, then plummeted by -71238bps to 429034.78% in 2022, then skyrocketed by 100bps to 41.53% in 2023.
  • Per Business Quant, the three most recent readings for DNLI's Net Margin are 41.53% (Q4 2023), 7841.59% (Q3 2023), and 3667.66% (Q2 2023).